Interestingly, omalizumab, a therapeutic mAb blocking IgE binding to its high-affinity receptor FcεR I and administrated to severe cases of asthma, has been associated with higher risk of solid cancers development, suggesting that endogenous IgE may be part of the immunological host defense against tumors [130]. Here, IGHE is linked to asthma.